Lundbeck strongly disagrees with the Commission's decision and the General Court's judgment. Lundbeck's agreements did not restrict competition and did not go beyond the protection already offered by society via Lundbeck's patent rights. Over 600 meticulous analyses of generic citalopram samples demonstrated that the generic citalopram was produced with infringing processes. Furthermore, in many concurrent documents the generic companies acknowledged that their products violated Lundbeck's patents. Patent settlement agreements are efficiency enhancing and legitimate when there are bona fide grounds for dispute.